The Preclinical Imaging Research Laboratory (PIRL) is a shared resource of the Lombardi Comprehensive Cancer Center (Lombardi), formalized in 2006. The objective of the PIRL is to provide high-resolut6ion in vivo small animal imaging and image analysis for Lombardi researchers involved in the study of cancer initiation, progression, and interdiction/therapy. The high-end instruments in PIRL enable noninvasive, longitudinal studies of cancer in vivo. The PIRL provides expertise in the design, acquisition, and analysis of preclinical imaging studies using the following instrumentation: a Bruker 7-Tesla magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) console, a small-animal ultrasound (Vevo660) workstation, an X-ray imaging unit (Faxltron) and a visible-near infrared spectroscopic imaging workstation (Maestro II). Support from the Lombardi in 2008 allowed the PIRL to acquire the Maestro workstation, update imaging software for the Bruker magnet to Paravision 4.0, and hire Dr. Yi-Chien Lee to perform the MR imaging. Additional upgrades to the magnet will be completed in May of 2009. The PIRL provides drop-off imaging, as well as training sessions for investigator initiated image acquisition. All original MRI and MRS data regardless of who has performed the acquisition are analyzed by the PIRL using Bruker software that is licensed to the PIRL. The director, Christopher Albanese, PhD, Associate Professor of Oncology, is a molecular biologist with expertise in genetically engineered mouse modeling and imaging. The PIRL is co-directed by John VanMeter, PhD, director of the ST human fMRI facility at Georgetown University Medical Center, with over 15 years of expertise in medical imaging and software development and Dr. Olga Rodriguez, MD, PhD, an Assistant Professor of Oncology and an expert in preclinical MRI as well as clinical and preclinical pathology. In 2008, the PIRL was utilized by 13 Lombardi investigators from four Lombardi programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA051008-19
Application #
8375522
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2014-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
19
Fiscal Year
2012
Total Cost
$34,167
Indirect Cost
Name
Georgetown University
Department
Type
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
Lee, Yichien; Rodriguez, Olga C; Albanese, Chris et al. (2018) Divergent brain changes in two audiogenic rat strains: A voxel-based morphometry and diffusion tensor imaging comparison of the genetically epilepsy prone rat (GEPR-3) and the Wistar Audiogenic Rat (WAR). Neurobiol Dis 111:80-90
Coia, Heidi; Ma, Ning; Hou, Yanqi et al. (2018) Prevention of Lipid Peroxidation-derived Cyclic DNA Adduct and Mutation in High-Fat Diet-induced Hepatocarcinogenesis by Theaphenon E. Cancer Prev Res (Phila) 11:665-676
Ory, Virginie; Kietzman, William B; Boeckelman, Jacob et al. (2018) The PPAR? agonist efatutazone delays invasive progression and induces differentiation of ductal carcinoma in situ. Breast Cancer Res Treat 169:47-57
Ozawa, Patricia Midori Murobushi; Alkhilaiwi, Faris; Cavalli, Iglenir João et al. (2018) Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells. Breast Cancer Res Treat 172:713-723
Smith, Jill P; Wang, Shangzi; Nadella, Sandeep et al. (2018) Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice. Cancer Immunol Immunother 67:195-207
Edwardson, Matthew A; Zhong, Xiaogang; Fiandaca, Massimo S et al. (2018) Plasma microRNA markers of upper limb recovery following human stroke. Sci Rep 8:12558
Kaat, Aaron J; Schalet, Benjamin D; Rutsohn, Joshua et al. (2018) Physical function metric over measure: An illustration with the Patient-Reported Outcomes Measurement Information System (PROMIS) and the Functional Assessment of Cancer Therapy (FACT). Cancer 124:153-160
Maximov, Philipp Y; Abderrahman, Balkees; Fanning, Sean W et al. (2018) Endoxifen, 4-Hydroxytamoxifen and an Estrogenic Derivative Modulate Estrogen Receptor Complex Mediated Apoptosis in Breast Cancer. Mol Pharmacol 94:812-822
Czarnecka, Magdalena; Lu, Congyi; Pons, Jennifer et al. (2018) Neuropeptide Y receptor interactions regulate its mitogenic activity. Neuropeptides :
Gonzalez, Thomas L; Moos, Rebecca K; Gersch, Christina L et al. (2018) Metabolites of n-Butylparaben and iso-Butylparaben Exhibit Estrogenic Properties in MCF-7 and T47D Human Breast Cancer Cell Lines. Toxicol Sci 164:50-59

Showing the most recent 10 out of 1120 publications